Moderna, Inc. $MRNA Stock Sold by Montaka Global Pty Ltd

Montaka Global Pty Ltd lessened its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 41.0% in the third quarter, HoldingsChannel.com reports. The fund owned 11,775 shares of the company’s stock after selling 8,175 shares during the period. Moderna accounts for about 0.9% of Montaka Global Pty Ltd’s investment portfolio, making the stock its 24th largest holding. Montaka Global Pty Ltd’s holdings in Moderna were worth $2,268,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Lido Advisors LLC lifted its position in Moderna by 0.5% during the third quarter. Lido Advisors LLC now owns 16,605 shares of the company’s stock valued at $3,198,000 after purchasing an additional 83 shares during the last quarter. Keybank National Association OH grew its stake in Moderna by 5.6% in the 3rd quarter. Keybank National Association OH now owns 9,581 shares of the company’s stock worth $1,845,000 after buying an additional 512 shares in the last quarter. 71 West Capital Partners purchased a new position in Moderna in the 3rd quarter worth approximately $494,000. Gryphon Financial Partners LLC purchased a new position in Moderna in the 3rd quarter worth approximately $470,000. Finally, AlphaCore Capital LLC bought a new position in shares of Moderna in the 3rd quarter worth $499,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Moderna stock opened at $250.83 on Wednesday. The firm has a fifty day simple moving average of $196.68 and a two-hundred day simple moving average of $93.60. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $280.80. The company has a market capitalization of $101.49 billion, a PE ratio of -35.33 and a beta of 1.16.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $890.25 million. During the same period last year, the firm earned ($0.51) earnings per share. The company’s revenue for the quarter was up 29.2% compared to the same quarter last year. Research analysts expect that Moderna, Inc. will post -5.69 EPS for the current year.

Insider Activity

In other news, President Stephen Hoge sold 39,145 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $220.72, for a total value of $8,640,084.40. Following the completion of the sale, the president owned 1,636,565 shares of the company’s stock, valued at approximately $361,222,626.80. The trade was a 2.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Jamey Mock sold 34,836 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the sale, the chief financial officer owned 59,375 shares of the company’s stock, valued at $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 197,251 shares of company stock valued at $33,875,904. Insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Loop Capital set a $135.00 price objective on shares of Moderna in a research report on Wednesday, August 19th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Moderna in a report on Friday, September 25th. Jefferies Financial Group reiterated a “hold” rating and issued a $150.00 target price (up from $60.00) on shares of Moderna in a research report on Wednesday, August 19th. JPMorgan Chase & Co. increased their target price on Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a research note on Friday, August 21st. Finally, Argus raised Moderna from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research note on Friday, August 28th. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $113.75.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of about $1.3 billion, up 29% year over year and ahead of expectations, and raised its 2026 revenue-growth outlook to 15%–25%. Lower costs and respiratory-vaccine gains also supported the improved outlook. Why is Moderna stock soaring today?
• Positive Sentiment: Investors also have a potential longer-term catalyst in personalized cancer vaccine intismeran. Phase 3 results reportedly showed a 42% reduction in melanoma recurrence or death, and Moderna is targeting an FDA filing by year-end 2026, which could lead to a decision in 2027. Can Moderna’s first cancer therapy win FDA approval in 2027?
• Neutral Sentiment: Moderna is scheduled to present at the Jefferies Global Health Care Conference on November 18. The event could provide updates, but the announcement itself does not change the company’s outlook. Moderna to present at upcoming conference
• Negative Sentiment: Despite the earnings beat, nearly all of Moderna’s revenue still comes from COVID-related products, leaving investors focused on the challenge of building durable sales beyond the pandemic market. That concern may weigh more heavily after the stock’s sharp recent run. Moderna’s Q3 numbers may not be enough to make the stock a buy
• Negative Sentiment: Valuation is another headwind: Goldman Sachs raised its price target but kept a neutral rating, while a separate analysis put fair value well below the prevailing share price. Brookline also made modest reductions to its long-term earnings estimates, despite maintaining a Buy rating.

About Moderna

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.